Efficacy and Safety of Naftopidil in Patients With Neurogenic Lower Urinary Tract Dysfunction: An 8-Week, Active-Controlled, Stratified-Randomized, Double-Blind, Double-Dummy, Parallel Group, Noninferiority, Multicenter Design
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the efficacy and safety of naftopidil compared with tamsulosin in patients with neurogenic lower urinary tract dysfunction (LUTD). Methods: This study was conducted as an 8-week, active-controlled, stratified-randomized, double-blind, double-dummy, parallel group, noninferiority, and multicenter clinical trial. After 2 weeks of screening, eligible subjects were randomly assigned to receive naftopidil (25 mg for 1 week followed by 75 mg for 7 weeks) or tamsulosin (0.2 mg for 8 weeks). Primary endpoint was a change of International Prostatic Symptom Score (IPSS) total score after 8 weeks of treatment. Results: One hundred ninety-four subjects with neurogenic LUTD were included into this trial. There were no differences between the 2 groups in baseline characteristics, including urodynamic study results, subtype of LUTD, pretreatment and concomitant medication, and causes of neurogenic bladder. The medication compliance rate was 94.0% (naftopidil, 93.6%; tamsulosin, 94.4%). There was a statistically significant decrease of IPSS total score at 8 weeks versus baseline in both the naftopidil (-5.64±0.66) and tamsulosin (-6.53±0.65) groups (P<0.0001 each). The mean difference between both groups was 0.89 (upper limit of 95% confidential interval, 2.72), which was lower than the noninferiority limit of 3 points. A subgroup analysis of neurologic lesions and sex found no mean difference of IPSS total score in each group. There was also no difference in safety profiles, including treatment emergent adverse events. Conclusions: Naftopidil was not inferior to tamsulosin as a therapeutic drug for patients with neurogenic LUTD and had a similar safety profile.
Abstract
Purpose: The aim of this study was to evaluate the efficacy and safety of naftopidil compared with tamsulosin in patients with neurogenic lower urinary tract dysfunction (LUTD). Methods: This study was conducted as an 8-week, active-controlled, stratified-randomized, double-blind, double-dummy, parallel group, noninferiority, and multicenter clinical trial. After 2 weeks of screening, eligible subjects were randomly assigned to receive naftopidil (25 mg for 1 week followed by 75 mg for 7 weeks) or tamsulosin (0.2 mg for 8 weeks). Primary endpoint was a change of International Prostatic Symptom Score (IPSS) total score after 8 weeks of treatment. Results: One hundred ninety-four subjects with neurogenic LUTD were included into this trial. There were no differences between the 2 groups in baseline characteristics, including urodynamic study results, subtype of LUTD, pretreatment and concomitant medication, and causes of neurogenic bladder. The medication compliance rate was 94.0% (naftopidil, 93.6%; tamsulosin, 94.4%). There was a statistically significant decrease of IPSS total score at 8 weeks versus baseline in both the naftopidil (-5.64±0.66) and tamsulosin (-6.53±0.65) groups (P<0.0001 each). The mean difference between both groups was 0.89 (upper limit of 95% confidential interval, 2.72), which was lower than the noninferiority limit of 3 points. A subgroup analysis of neurologic lesions and sex found no mean difference of IPSS total score in each group. There was also no difference in safety profiles, including treatment emergent adverse events. Conclusions: Naftopidil was not inferior to tamsulosin as a therapeutic drug for patients with neurogenic LUTD and had a similar safety profile.
참고문헌 (24)
- Abrams P, "Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury", J Urol, 170(4 Pt 1), pp.1242~1251 (2003)
- Eldahan KC, "Autonomic dysreflexia after spinal cord injury : systemic pathophysiology and methods of management", Auton Neurosci, 209, pp.59~70 (2018)
- Schwinn DA, "Alpha1-adrenoceptor subtypes and lower urinary tract symptoms", Int J Urol, 15, pp.193~199 (2008)
- Gu BJ, "Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction", J Urol, 167, pp.1887~1891 (2002)
- 김도경, "Alpha-1 Adrenergic Receptor Blockers for the Treatment of Lower Urinary Tract Symptoms in Women: A Systematic Review and Meta-Analysis", International Neurourology Journal, 23(1), pp.56~68 (2019), 대한배뇨장애요실금학회[DOI]
- Takeda M, "Predictive factors for the effect of the α1-D", A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction, 2011, pp.108, 100~107
- Shibata K, "KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist:characterization using recombinant human alpha 1-adrenoceptors and native tissues", Mol Pharmacol, 48, pp.250~258 (1995)
- Takei R, "Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors", Jpn J Pharmacol, 79, pp.447~454 (1999)
- Hwang EC, "Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia", Cochrane Database Syst Rev, 10, pp.CD007360~ (2018)
- 조성용, "Translation and Linguistic Validation of the Korean Version of the “Benefit, Satisfaction, and Willingness to Continue” Questionnaire for Patients With Overactive Bladder", International Neurourology Journal, 20(3), pp.255~259 (2016), 대한배뇨장애요실금학회
- Kakizaki H, "Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder", Int J Urol, 10, pp.576~581 (2003)
- Chancellor MB, "Prospective evaluation of terazosin for the treatment of autonomic dysreflexia", J Urol, 151, pp.111~113 (1994)
- Ueda S, "Alpha 1-and alpha 2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra", Eur J Pharmacol, 103, pp.249~254 (1984)
- Andersson K, "alpha1-adrenoceptors and bladder function", Eur Urol, 36(Suppl 1), pp.96~102 (1999)
- Cameron AP, "Combination drug therapy improves compliance of the neurogenic bladder", J Urol, 182, pp.1062~1067 (2009)
- Wada N, "Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury", Neurourol Urodyn, 36, pp.1039~1045 (2017)
- Romo PGB, "Non-surgical urologic management of neurogenic bladder after spinal cord injury", World J Urol, 36, pp.1555~1568 (2018)
- Phillips AA, "Selective alpha adrenergic antagonist reduces severity of transient hypertension during sexual stimulation after spinal cord injury", J Neurotrauma, 32, pp.392~396 (2015)
- Krum H, "A study of the alpha-1adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients", Clin Auton Res, 2, pp.83~88 (1992)
- Bennett JK, "Terazosin for vesicosphincter dyssynergia in spinal cordinjured male patients", Mol Urol, 4, pp.415~420 (2000)
- Smith MS, "Alpha1-adrenergic receptors in human spinal cord : specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels", Brain Res Mol Brain Res, 63, pp.254~261 (1999)
- Hampel C, "Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction", J Urol, 167, pp.1513~1521 (2002)
- Malloy BJ, "Alpha1-adrenergic receptor subtypes in human detrusor", J Urol, 160(3 Pt 1), pp.937~943 (1998)
- Ishida H, "α1DAdrenoceptor blockade increases voiding efficiency by improving external urethral sphincter activity in rats with spinal cord injury", Am J Physiol Regul Integr Comp Physiol, 311, pp.R971~R978 (2016)